PMV Pharmaceuticals
PMVP
63 hedge funds and large institutions have $46.8M invested in PMV Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 22 increasing their positions, 18 reducing their positions, and 10 closing their positions.
22% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 18
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 10
0.43% less ownership
Funds ownership: 70.75% → 70.33% (-0.43%)
2% less funds holding
Funds holding: 64 → 63 (-1)
11% less capital invested
Capital invested by funds: $52.5M → $46.8M (-$5.71M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
+$611K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$610K |
| 3 |
Two Sigma Investments
New York
|
+$585K |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
+$207K |
| 5 |
Jane Street
New York
|
+$156K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$1.34M |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$294K |
| 3 |
PLC
Peapod Lane Capital
Bedford Hills,
New York
|
-$284K |
| 4 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$283K |
| 5 |
BFM
Boothbay Fund Management
New York
|
-$234K |
PMVP Hedge Fund Activity: Q4 2025 in Review
63 of the 8,280 institutional investors tracked by Wall St. Rank reported a position in PMV Pharmaceuticals (PMVP) for Q4 2025, worth a combined $46.8M — down 11% from $52.5M a quarter earlier.
Fund positioning in PMVP was balanced in Q4 2025: 10 funds opened new positions, 10 closed out, 22 added to existing stakes and 18 trimmed.
The largest buyer was Two Sigma Advisers, adding an estimated $611K. The largest seller was OrbiMed, cutting an estimated $1.34M.
- 63 institutional investors held PMV Pharmaceuticals (PMVP) as of Q4 2025, down from 64 in Q3 2025.
- Funds reported $46.8M of PMV Pharmaceuticals stock for Q4 2025, down 11% quarter-over-quarter.
- 10 funds opened new PMV Pharmaceuticals positions in Q4 2025 and 10 closed out, a net change of 0 holders.
- The largest PMV Pharmaceuticals buyer in Q4 2025 was Two Sigma Advisers, an estimated $611K added.
- The largest PMV Pharmaceuticals seller in Q4 2025 was OrbiMed, an estimated $1.34M sold.
Based on aggregated 13F filings for Q4 2025.